Multimed, the publisher of Current Oncology, is pleased to partner with organizations, associations and industry across Canada, to publish supplementa

 
CO-NEWSLETTER-LOGO withdate
ESMO-Web-Banner560x100
***

Multimed, the publisher of Current Oncology, is pleased to partner with organizations, associations and industry across Canada, to publish supplemental issues devoted to specific topics that are of interest and importance to the Canadian oncology community. We have a shared vision and common goal with our partners to educate professionals and to share knowledge that will have an impact on the future practice of cancer medicine. Supplements to peer reviewed and high-impact journals, such as Current Oncology, are effective tools for delivering important research and critical findings to oncology professionals in Canada, and on a global scale.

High-Value Content Covering Cancer Costing and Cannabinoids in Cancer Care - Coming 2016!

Canadian Cancer Costing Research
This supplement is co-edited by Dr. Nicole Mittmann (Cancer Care Ontario, Toronto, ON) and Dr. Claire de Oliveira (Centre for Addiction and Mental Health, Toronto, ON), and will focus on original Canadian cancer costing research that evaluates various themes such as burden of illness, population health modelling, costs of programs and policies, costs borne by patients, and much more. The submission deadline for this supplement was October 15th, and we received an astounding response. Thank you to all authors for your interest in publishing with Current Oncology.

Use of Cannabinoids in Cancer Care
The potential for cannabinoid therapies to play a role in cancer management, from symptom control to palliation to disease modification, is gathering a great deal of public interest and demand for action from industry and academia. The special supplemental issue, Guest Edited by Dr. Mark Ware (McGill University Health Centre), will contain comprehensive reviews of these topics by national and international experts in the field, to inform and guide our clinical practice and research priorities in the coming years.

Do you have an idea or suggestions for a special topic of interest to the Canadian oncology community? Send an email to current_oncology@multi-med.com.

logo70

Multimed Inc.
Publisher of Current Oncology
www.multi-med.com

***
CO Twitter Banner Ad
***
InPress-CON

Volume 22, Number 5 (October 2015)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:
http://www.current-oncology.com/index.php/oncology/issue/current/showToc

CO-COVER-ISSUE

Highlights from this issue...

In the October issue, we revisit the mammography debate. Constantine Kaniklidis (Research Director, No Surrender Breast Cancer Foundation) helps guide readers through the fog in his Editorial “The mammography debate, round two: science, smoke and mirrors”. He has also gathered contributions from several experts across the globe to contribute to this debate, and the science behind it.

LookingAhead-CON

Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 22, Number 6 (December 2015) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:
http://www.current-oncology.com/index.php/oncology/about/futureTOC

***
ImpactFactor2014
***
EditorSpotlight
SGill

Sharlene Gill, BSc (Pharm), MD, MPH, FACP, FRCP(C)
Editor of our Medical Oncology Section (since April 2013)

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies. She received a Bachelor’s of Science in Pharmacy (Honors) and an MD (Doctor of Medicine) from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology. Dr. Gill subsequently completed a fellowship in GI Oncology at the Mayo Clinic (Rochester, MN) and a Master’s of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver, Canada where she is currently an Associate Professor of Medicine at the University of British Columbia and an academic GI oncologist at the BC Cancer Agency. In addition to her medical practice, she is actively involved in education, clinical trials and research. Her areas of expertise are colorectal, hepatobiliary and pancreatic cancers. She is also presently completing her MBA studies from the Kenan-Flagler Business School (University of North Carolina). Dr. Gill serves on editorial boards and is an active reviewer for several journals, and has over 60 peer-reviewed publications and book chapters to her credit.

***
HaveYouHeard-CON

No Authors Fees for Clinical Research and Clinical Trial Articles: Until Dec 31, 2015

560x100 Banner

Current Oncology is seeking high-quality original clinical research and clinical trial articles. Areas may include research related to treatment, prevention, diagnostic, screening, and quality of life. Articles submitted should contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.

To help encourage submissions, Current Oncology will waive Standard Author Fees for all original clinical research and clinical trial articles, submitted between July 1st and December 31st, 2015.

View our full announcement for more details.

***

Current Oncology Welcomes Dr. Naheed Dosani to our Editorial Team

We are pleased to welcome Dr. Naheed Dosani (William Osler Health System: Brampton Civic Hospital) to the Editorial Team as co-editor of the journal’s Palliative Care section. To view Current Oncology’s full list of Section Editors, please click here.

***

October is Breast Cancer Awareness Month!

In the interest of breast cancer awareness month, we invite you to review articles from our recently published supplement titled “Updated Guidelines, Consensus and Evidence-Based Reports in Breast Cancer”. The supplement, edited by Dr. Maureen Trudeau (Sunnybrook Health Sciences Centre, Toronto, ON), contains up to date and evidence-based guidelines and consensus statements in breast cancer, including those completed by Cancer Care Ontario’s Program in Evidence Based Care. There are also reviews covering outcome of patients with pregnancy during or after breast cancer, targeted therapy in HER2-positive metastatic breast cancer, and systemic treatment in HER2-neagative advanced breast cancer. To view the full-text articles from this special issue, visit http://www.current-oncology.com/index.php/oncology/issue/view/92/showToc.

***

50th Anniversary of the Discovery of the CEA

Phil-Gold cropped11-253x300

This year marks the 50th anniversary of the discovery of the Carcinoembryonic Antigen (CEA), by Dr. Phil Gold (Deputy Editor, Current Oncology), and his colleague Dr. Samuel Freedman. This discovery revolutionized cancer research and is now the most frequently used blood test in modern oncology.

Congratulations to Dr. Gold, who was recently honoured at the 25th Annual International CEA Symposium held in Washington, and the 42nd Congress of the International Society for Oncology and Biomarkers held in Poland. Click here to view the full announcement.

***
ReadersChoice-COn

Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (October 2015)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

Management of arthralgias associated with aromatase inhibitor therapy
Thorne C.
Curr Oncol. 2007 Dec;14 Suppl 1:S11-9

Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature
Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C.
Curr Oncol. 2010 Aug;17(4):94-112

Most Read Recently* Published Articles at www.current-oncology.com

A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults
Seftel MD, Barnett MJ, Couban S, Leber B, Storring J, Assaily W, Fuerth B, Christofides A, Schuh AC.
Curr Oncol. 2014 Oct;21(5):234-50. doi: 10.3747/co.21.2183

Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations
Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Gross PL, Blais N, Butts CA, Crowther M
Curr Oncol. 2015 Feb;22(1):49-59. doi: 10.3747/co.22.2392

Locoregional therapy of locally advanced breast cancer: a clinical practice guideline
Brackstone M, Fletcher GG, Dayes IS, Madarnas Y, SenGupta SK, Verma S; Members of the Breast Cancer Disease Site Group
Curr Oncol. 2015 Mar;22(Suppl 1):S54-66. doi: 10.3747/co.22.2316

*Published within past 12 months

***
300 x 80px-01

#YARally

StephanieMadsen2

Stay tuned as CKN partners with Stephanie Madsen in our young adult (YA) cancer campaign aimed to improve care for YA cancer patients through social media education and awareness. Our goal is to make the voices of YAs with cancer heard so that improvements can be made and standardized within the greater healthcare community. We’ll tackle the hard issues like body image, sexuality, dating and fertility. Follow us on twitter: @cancerkn.

Fertility Database

CKNLogo SquareColoured

CKN and the Canadian Fertility and Andrology Society (CFAS) have recently partnered to create the first Canadian fertility database for cancer patients. With the support of fertility clinics across Canada, we will collect data from cancer patient referrals which will help us determine who is making referrals (medical oncology, radiation oncology, surgical oncology, gynecologic oncology, family medicine etc.), as well as allowing us to monitor patient decision-making regarding the use of available technology to preserve fertility before cancer treatment begins. We’re very excited to see where this information leads us in 2016.

***
QuickLinks-CON
***

Contact Us

Email-CON
 
Address-CON
 
Phone-CON
 
Web-CON
twitter
1px